The following is a statement provided by BioMatrix.
“BioMatrix Specialty Pharmacy is closely monitoring the COVID-19 pandemic. Our organization has initiated properÂ response measures to ensure bleeding disorder patients maintain access to the specialty drugs required to effectivelyÂ manage their condition throughout this emergent situation. BioMatrix is leveraging its national footprint, detailedÂ business continuity plans, and extensive assets to ensure there is no disruption in patient care.
We have allocated additional resources and enacted risk mitigation plans, including early refills or additional suppliesÂ when and where appropriate. We have opened additional communication channels including a COVID-19 response pageÂ on our website and a SMS text system increasing pharmacist communication with our patients. Our team has remainedÂ in close contact with drug manufacturers, wholesalers, and suppliers and we do not anticipate any interruption in accessÂ to the products and supplies our bleeding disorder patients require.
We continue to monitor guidance from the World Health Organization, the CDC, FDA, the Boards of Pharmacy, andÂ other healthcare regulatory bodies at the national, regional, state, and county levels to stay abreast of impact, guidanceÂ and trends. We understand the importance of continuity for the bleeding disorders community and we are confidentÂ that working together with organizations such as the National Hemophilia Foundation we will rise to overcome anyÂ challenges associated with COVID-19.”